Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)

NCT05980000 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05980000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05980000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 27, 2023
Completion date
June 30, 2030
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc, metastatic head and neck cancer, metastatic head-and-neck squamous-cell carcinoma, recurrent head and neck cancer, recurrent head and neck carcinoma, recurrent head and neck squamous cell carcinoma